论文部分内容阅读
目的探索应用胃泌素受体拮抗剂调控胃癌细胞自分泌生长的作用及其机制。方法建立胃癌细胞株ＭＫＮ４５移植瘤的动物模型，观察胃泌素受体拮抗剂丙谷胺对移植瘤的面积、重量、胃癌细胞ＤＮＡ及血清促胃液素含量的影响。结果第１６天丙谷胺组移植瘤面积（６１．４１±１８．５７）ｍｍ２较对照组（９４．８６±２８．０５）ｍｍ２明显缩小（Ｐ＜０．０５），第２８天时差别更明显（１２５．５７±４０．２６）∶（２１１．５９±５０．０８）ｍｍ２。第２８天时丙谷胺组及对照组的移植瘤重量分别为（８４７．９±６９．６）ｍｇ及（１１７７．７±８３．５）ｍｇ（Ｐ＜０．０５）。丙谷胺组胃癌细胞ＤＮＡ指数、平均ＤＮＡ含量及Ｓ期细胞比例均低于对照组。丙谷胺对血清促胃液素含量没有影响。结论丙谷胺对胃癌细胞株ＭＫＮ４５移植瘤有抑制生长的作用；丙谷胺发挥抗肿瘤作用是通过改变胃癌细胞ＤＮＡ代谢过程，而与血清促胃液素含量的改变无关。
Objective To explore the effect and mechanism of gastrin receptor antagonists on autocrine growth of gastric cancer cells. METHODS: An animal model of gastric cancer cell line MKN45 xenograft was established. The effects of progagitin, a gastrin receptor antagonist, on the area and weight of xenograft tumors, DNA of gastric cancer cells, and serum gastrin levels were observed. Results On the 16th day, the tumor area of the proglumide group (61.41±18.57) mm2 was significantly smaller than that of the control group (94.86±28.05) mm2 (P<0.05). The difference was more obvious on the 28th day. (125.57±40.26): (211.59±50.08) mm2. On the 28th day, the tumor weights of proglumide group and control group were (847.9±69.6) mg and (1177.7±83.5) mg, respectively (P<0.05). The DNA index, average DNA content, and proportion of S-phase cells in the proglumide group were lower than those in the control group. Proglumide had no effect on serum gastrin levels. Conclusion Proglumide can inhibit the growth of gastric cancer cell line MKN45 xenografts. Proglutamine exerts its anti-tumor effect by changing the DNA metabolism of gastric cancer cells, but has nothing to do with the change of serum gastrin content.